https://claritaspharma.com/ 2023-10-13 https://claritaspharma.com/chairmans-blog/ 2023-10-13 https://claritaspharma.com/chairmans-blog/a-message-from-our-chairman/ 2023-10-13 https://claritaspharma.com/cookie-policy/ 2023-10-13 https://claritaspharma.com/for-investors/faq/ 2023-10-13 https://claritaspharma.com/for-investors/financial-information/ 2023-10-13 https://claritaspharma.com/for-investors/investors/ 2023-10-13 https://claritaspharma.com/our-company-our-products-in-development/cla-1816-for-treatment-of-pain/ 2023-10-13 https://claritaspharma.com/our-company-our-products-in-development/r-107-for-covid-viral-infections/ 2023-10-13 https://claritaspharma.com/our-company/overview/ 2023-10-13 https://claritaspharma.com/our-company/team/ 2023-10-13 https://claritaspharma.com/our-science/nitric-oxide-technology/ 2023-10-13 https://claritaspharma.com/our-science/r-107-for-covid/ 2023-10-13 https://claritaspharma.com/our-company/partnering/ 2023-10-13 https://claritaspharma.com/kalytera-therapeutics-inc-completes-name-change-to-claritas-pharmaceuticals-inc/ 2023-10-17 https://claritaspharma.com/claritas-pharmaceuticals-issues-letter-to-shareholders/ 2023-10-17 https://claritaspharma.com/claritas-pharmaceuticals-formerly-kalytera-therapeutics-to-focus-on-development-of-r-107-as-a-therapy-for-vaccine-resistant-covid-19-influenza-and-other-viral-infections/ 2023-10-17 https://claritaspharma.com/claritas-outlines-development-strategy-for-r-107-for-multiple-diseases-disorders-and-injuries/ 2023-10-17 https://claritaspharma.com/claritas-formerly-kalytera-therapeutics-inc-to-collaborate-with-salzman-group-and-other-companies-to-accelerate-development-of-r-107-for-treatment-of-vaccine-resistant-covid-19-influenza-and-oth/ 2023-10-17 https://claritaspharma.com/claritas-formerly-kalytera-therapeutics-inc-announces-addition-of-professor-salvatore-cuzzocrea-ph-d-to-the-companys-board-of-directors/ 2023-10-13 https://claritaspharma.com/claritas-formerly-kalytera-therapeutics-cites-breakthrough-data-by-massachusetts-general-hospital-and-others-demonstrating-the-effectiveness-of-nitric-oxide-as-a-potential-therapy-for-covid-19-infec/ 2023-10-17 https://claritaspharma.com/claritas-formerly-kalytera-therapeutics-announces-additional-program-to-reduce-the-rate-and-spread-of-covid-19-with-prophylactic-r-107-nasal-spray-designed-to-provide-sustained-release-of-nitric-oxi/ 2023-10-13 https://claritaspharma.com/claritas-cites-data-from-study-demonstrating-effectiveness-of-nitric-oxide-in-patients-with-severe-covid-19-pneumonia-as-validation-of-the-companys-nitric-oxide-releasing-compound-r-107/ 2023-10-17 https://claritaspharma.com/claritas-anticipates-response-from-australian-ethics-committee-by-february-18-2022/ 2023-10-17 https://claritaspharma.com/claritas-announces-transfer-of-gvhd-program-and-cancellation-of-related-debt-as-company-focuses-on-nitric-oxide-therapeutics/ 2023-10-17 https://claritaspharma.com/claritas-announces-results-of-annual-general-and-special-meeting-of-shareholders/ 2023-10-17 https://claritaspharma.com/claritas-announces-publication-of-peer-reviewed-article-reporting-that-r-107-significantly-improved-multi-organ-function-and-survival-in-an-ovine-sheep-model-of-sepsis/ 2023-10-17 https://claritaspharma.com/claritas-announces-letter-of-intent-to-acquire-worldwide-rights-to-r-107-for-treatment-of-wound-healing-skin-ulcers-and-severe-burns/ 2023-10-17 https://claritaspharma.com/claritas-announces-formation-of-nitric-oxide-scientific-advisory-board/ 2023-10-17 https://claritaspharma.com/claritas-announces-completion-of-ind-enabling-rodent-toxicology-studies-with-r-107/ 2023-10-17 https://claritaspharma.com/claritas-announces-completion-of-ind-enabling-in-vitro-genotoxicity-studies-with-r-107/ 2023-10-17 https://claritaspharma.com/claritas-announces-completion-of-canine-toxicology-studies/ 2023-10-17 https://claritaspharma.com/claritas-announces-approval-from-australian-ethics-committee-to-begin-phase-1-trial-of-r-107/ 2023-10-17 https://claritaspharma.com/claritas-announces-appointment-of-robert-farrell-j-d-as-chairman-of-the-companys-board-of-directors/ 2023-10-17 https://claritaspharma.com/claritas-announces-agreement-with-cmax-clinical-research-for-phase-1-clinical-study-of-r-107/ 2023-10-17